Cargando…

Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

Janus kinase (JAK) enzymes are involved in cell signaling pathways activated by various cytokines dysregulated in allergy. The objective of this study was to determine whether the novel JAK inhibitor oclacitinib could reduce the activity of cytokines implicated in canine allergic skin disease. Using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzales, A J, Bowman, J W, Fici, G J, Zhang, M, Mann, D W, Mitton-Fry, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Scientific Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265276/ https://www.ncbi.nlm.nih.gov/pubmed/24495176 http://dx.doi.org/10.1111/jvp.12101

Ejemplares similares

A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(®)) in client‐owned dogs with atopic dermatitis
por: Cosgrove, Sallie B., et al.
Publicado: (2013)

Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia
por: Gadeyne, Caroline, et al.
Publicado: (2014)

Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis
por: Visser, Marike, et al.
Publicado: (2022)

A retrospective evaluation of the effect of oclacitinib (Apoquel) administration on development of surgical site infection following clean orthopedic stifle surgery
por: Motz, Alyssa K., et al.
Publicado: (2023)

Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks
por: Panteri, Alessandro, et al.
Publicado: (2015)

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis
por: Cosgrove, Sallie B, et al.
Publicado: (2013)

A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs
por: Little, Peter R, et al.
Publicado: (2015)

Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-γ-, Producing Murine CD4(+) and CD8(+) T Cells and Counteracts the Induction of Type 1 Regulatory T Cells
por: Jasiecka-Mikołajczyk, Agnieszka, et al.
Publicado: (2021)

Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
por: Picca, Alberto, et al.
Publicado: (2021)

Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib
por: Ashton, Laura V, et al.
Publicado: (2020)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
por: Lopes, Natália Lôres, et al.
Publicado: (2019)

Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib
por: Mwacalimba, Kennedy, et al.
Publicado: (2023)

Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma
por: Ashton, Laura V., et al.
Publicado: (2023)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation
por: Ortmann, Robert A, et al.
Publicado: (2000)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Evaluation of topical oclacitinib and nail trimming as a treatment for murine ulcerative dermatitis in laboratory mice
por: Davison, Steven E., et al.
Publicado: (2022)

Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
por: Harvey, Richard G., et al.
Publicado: (2022)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
por: Dowty, Martin E., et al.
Publicado: (2019)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study
por: Rynhoud, Hester, et al.
Publicado: (2021)

Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study
por: Barrett, Laura E., et al.
Publicado: (2019)

Inherited Sensory and Autonomic Neuropathy in a Border Collie, Interest of Oclacitinib for the Control of Self-Mutilation
por: Leonard, Caroline, et al.
Publicado: (2022)

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
por: Richardson, Peter J., et al.
Publicado: (2023)

The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
por: Rynhoud, Hester, et al.
Publicado: (2022)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Redox regulation of Janus kinase: The elephant in the room
por: Duhé, Roy J
Publicado: (2013)

Analysis of the involvement of cytokines in allergy and breast cancer association
por: Kowalczewska, Małgorzata E., et al.
Publicado: (2014)

Inhalational anesthesia maintenance with the Janus facial mask for transcatheter aortic-valve replacement: a case series
por: Nigro Neto, Caetano, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_miet3v5qsgem0tf22vho3l07s3